Track: CME Session
Track: Hybrid Session
Kyle Blum, MD, MS
University of Texas Houston, MD Anderson Cancer Center, Texas, United States
Disclosure(s): No financial relationships to disclose
Allison May, MD
University of Michigan
Ann Arbor, Michigan, United States
Disclosure(s): No financial relationships to disclose
Stephanie Berg, DO (she/her/hers)
Dana-Farber Cancer Institute
Needham, Massachusetts, United States
Disclosure(s): Non-CE Consulting: BMS (Ongoing); Exelixis (Ongoing); Pfizer (Ongoing); Sanofi (Ongoing); SeaGen (Ongoing)
Non-CE Speakers Bureau: BMS (Terminated, June 30, 2022); Eisai (Terminated, June 30, 2022); Exelixis (Terminated, June 30, 2022)
Steven Chang, MD, MS
Dana-Farbe/Brigham and Women's Cancer Center
Boston, Massachusetts, United States
Disclosure(s): No financial relationships to disclose
Payal Kapur, MD
University of Texas Southwestern
Disclosure(s): No financial relationships to disclose
Ivan Pedrosa, MD PhD
University of Texas Southwestern
Disclosure(s): No relevant disclosure to display
Chad Tang, MD
University of Texas MD Anderson Cancer Center
Disclosure(s): Non-CE Consulting: Diffusion Pharmaceuticals (Ongoing)
Non-CE Speakers Bureau: Bayer (Terminated, September 28, 2021)
Royalty: Wolters Kluwer (Ongoing)
David Braun, MD, PhD
Yale School of Medicine
New Haven, Connecticut, United States
Disclosure(s): Advisory board: Exelixis and AVEO (Ongoing)
Honoraria: Education/Exchange Services (Ongoing)
nonfinancial support from Bristol Myers Squibb: BMS (Terminated)
personal fees: Aptitude Health, and AbbVie (Ongoing); Charles Rever Associates, Schlesinger Associates, Imprint Science, Insight Strategy, Trinity Group, Cancer Expert Now, Adnovate Stategies, MDedge, CancerNetwork, Catenion, OncLive, Cello Health BioConsulting, PWW Consulting, Haymarket Medical Network (Ongoing)
research grant: Exelixis (Ongoing)
Jodi Maranchie, MD
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States
Disclosure(s): No financial relationships to disclose
Pavlos Msaouel, MD, PhD
University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Disclosure(s): Non-CE Consulting: Mirati Therapeutics (Terminated, June 7, 2021)
Srinivas Viswanathan, MD, PhD
Dana-Farber Cancer Institute
Disclosure(s): Non-CE Consulting: Jnana therapeutics (Terminated, June 25, 2022); MPM Capital (Terminated, June 25, 2022); Vida Ventures (Terminated, June 25, 2022)
Speaker: Jodi Maranchie, MD – University of Pittsburgh Medical Center
Speaker: David A. Braun, MD, PhD – Yale School of Medicine
Speaker: Srinivas R. Viswanathan, MD, PhD – Dana-Farber Cancer Institute
Speaker: Pavlos Msaouel, MD, PhD – University of Texas MD Anderson Cancer Center
Oral Abstract Presenter: Allison May, MD – University of Michigan
Oral Abstract Presenter: Kyle A. Blum, MD, MS – University of Texas Houston, MD Anderson Cancer Center
Panelist: Payal Kapur, MD – University of Texas Southwestern
Panelist: Ivan Pedrosa, MD PhD – University of Texas Southwestern
Panelist: Steven Chang, MD, MS – Dana-Farbe/Brigham and Women's Cancer Center
Panelist: Stephanie Berg, DO (she/her/hers) – Dana-Farber Cancer Institute
Panelist: Chad Tang, MD – University of Texas MD Anderson Cancer Center